Incyte pancreatic cancer drug improves survival in mid-stage trial

(Reuters) - Incyte Corp said a mid-stage trial of its experimental cancer treatment showed the drug, Jakafi, improved the survival rate of patients' most likely to benefit from the treatment. The company's shares rose 20 percent in premarket trade. The six month survival rate of patients treated with Jakafi along with chemotherapy was 42 percent, compared with an 11 percent survival rate for those on placebo. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/incyte-pancreatic-cancer-drug-improves-survival-mid-stage-114825477.html